BGB-A317-211

Recruiting

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Beigene Study ID info

BGB-A317-211

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20200972

Study Overview

Sex: All

Age: 18 Years to 70 Years   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years to 70 Years   (Adult, Older Adult)

No Study Documents